Mavefund EN
PROCYON CORP logo

PROCYON CORP

PCYN
Letzter Kurs (USD) US$0.25
Marktkapitalisierung (USD) US$2.0m
Kursänderung 12 Monate 145.10%
Loading the 12-month Mave Thesis and 1-month news signal

Start Heute Aktien Watchlist

PROCYON CORP Überblick

Branche: Drug Manufacturers Specialty & Generic

Sektor: Healthcare

Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems in the United States. It provides advanced skin and wound care products, including the hydrogel wound dressing products, post op surgical kits, saline wound washes, care lotions, and barrier lotions to promote healing in wound and problematic skin conditions, as well as hand sanitizer under the AMERIGEL brand name. The company also offers Advantagen, a surgical collagen powder that promotes wound closure and decreases the potential for surgical site infection; and rolled gauze wound care kits. In addition, it provides Bioactive Collagen products in the form of power and matrix under the HELIX3 brand name. Further, the company offers wound care products, such as calcium alginate, foam, gauze, and hyrdocolloid dressing products, as well as retention tapes; and wound care kits, which include calcium alginate, collagen matrix, collagen powder, foam, and hydrogel wound care kits under the AMERX brand name, as well as compression garment line products under the EXTREMIT-EASE brand name. It sells its products through distributors to institutional customers, such as hospitals, wound care clinics, nursing homes, home health agencies, physicians, and health care practitioners; and retail customers through direct sales, and internet sales, as well as through independent and retail chain drug stores. The company was incorporated in 1987 and is based in Oldsmar, Florida. Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems in the United States. It provides advanced skin and wound care products, includ

Research-Überblick

Letztes Berichtsdatum 2024-10-25

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu PROCYON CORP (PCYN): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
PCYN · OTC
Land
United States
Handelswährung
USD
Branche
Drug Manufacturers Specialty & Generic
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2024-10-25
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von PROCYON CORP für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Oct 25, 2024

Annual result summary

Latest company-filed earnings material is available for source review.

Was sich verändert hat

  • Review the source filing for the full reported results and management commentary.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the source document to review full management commentary.

SEC filing Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Keine qualifizierten Unternehmensnachrichten in den letzten 14 Tagen

Kein aktueller Artikel bestand sowohl die Unternehmensrelevanz- als auch die Quellenzuverlässigkeitsprüfung. Das Research nutzt weiterhin die übrigen verfügbaren Berichte, Fundamentaldaten, Marktdaten und Bewertungs-Inputs.

Gewinn je Aktie

Score 3.00/5
PROCYON CORP boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Eigenkapitalrendite

Score 2.22/5
PROCYON CORP exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
PROCYON CORP PCYN US$2.0m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Nettomarge

Score 3.36/5
PROCYON CORP commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
PROCYON CORP PCYN US$2.0m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Aktienrückkäufe

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Verschuldung

Score 2.87/5
PROCYON CORP attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
PROCYON CORP PCYN US$2.0m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

PROCYON CORP logo

PROCYON CORP

US$0.25

US$2.0m

0.00%

145.10%